Advertisement
U.S. markets close in 4 hours 7 minutes
  • S&P 500

    5,254.80
    +6.31 (+0.12%)
     
  • Dow 30

    39,783.33
    +23.25 (+0.06%)
     
  • Nasdaq

    16,402.74
    +3.22 (+0.02%)
     
  • Russell 2000

    2,131.14
    +16.79 (+0.79%)
     
  • Crude Oil

    82.71
    +1.36 (+1.67%)
     
  • Gold

    2,234.60
    +21.90 (+0.99%)
     
  • Silver

    24.91
    +0.16 (+0.64%)
     
  • EUR/USD

    1.0799
    -0.0030 (-0.28%)
     
  • 10-Yr Bond

    4.1870
    -0.0090 (-0.21%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.11%)
     
  • USD/JPY

    151.3160
    +0.0700 (+0.05%)
     
  • Bitcoin USD

    71,388.80
    +2,346.26 (+3.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,964.69
    +32.71 (+0.41%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

What Is The Future Prospect For Healthcare And Trevena Inc (NASDAQ:TRVN)?

Trevena Inc (NASDAQ:TRVN), a US$81m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector globally. Healthcare analysts are forecasting for the entire industry, a fairly unexciting growth rate of 4.6% in the upcoming year, and an enormous growth of 63% over the next couple of years. This rate is larger than the growth rate of the US stock market as a whole. Below, I will examine the sector growth prospects, and also determine whether Trevena is a laggard or leader relative to its healthcare sector peers. View our latest analysis for Trevena

What’s the catalyst for Trevena’s sector growth?

NasdaqGS:TRVN Past Future Earnings October 18th 18
NasdaqGS:TRVN Past Future Earnings October 18th 18

NasdaqGS:TRVN Past Future Earnings October 18th 18 Notably, Maxine Gowen, Ph.D., retired as the Company’s President and Chief Executive Officer, effective as of October 1, 2018. On September 27, 2018, Adam M. Koppel, M.D., Ph.D., provided the Company with notice of his resignation from the Board of Directors of the Company (the “Board”), effective as October 1, 2018. On October 11 Trevena, Inc. (NASDAQ: TRVN), announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss oliceridine. The Committee voted 8 against, and 7 in favor of, the approval of oliceridine for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. The stock dropped from over $3.40 on October 3 to under $1 on October 9.

Next Steps:

Before you make a decision on the stock, I suggest you look at Trevena’s fundamentals in order to build a holistic investment thesis.

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.

  2. Historical Track Record: What has TRVN’s performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

  3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of Trevena? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements. The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

Advertisement